Two senior scientists say National Institutes of Health officials advised them to remove references to mRNA vaccines in grant ...

As we near the five-year anniversary of the COVID-19 pandemic, it's a good time to revisit the drugmaker stock that was top ...

Moderna (MRNA) stock is climbing 8% after the drug maker won a key court case and its CEO bought shares on the open market.

Moderna (NASDAQ:MRNA) shares jumped 16% on Wednesday, March 5, following a favorable German court decision that determined ...

Citigroup assumed coverage on shares of Moderna (NASDAQ:MRNA – Free Report) in a research report report published on Thursday morning, MarketBeat.com reports. The brokerage issued a neutral rating and ...

Shares of the American pharmaceutical company Moderna (MRNA) climbed over 8% in pre-market trading following strategic ...

Moderna's legal win boosts stock but highlights mRNA technology struggles. Discover why MRNA stock may not sustain long-term ...

The Florida surgeon general in January called for a halt in the use of covid mRNA vaccines. And in Texas, Attorney General ...

Now the nation’s top health official, Kennedy is reevaluating the US Health and Human Services’s contract with Moderna, which ...

Citi initiated coverage of Moderna (MRNA) with a Neutral rating and $40 price target Healthcare policy remains a key biopharma sector ...

HHS is re-evaluating a nearly $600 million contract with Moderna to develop and test vaccines against flu viruses that could ...

In this article, we are going to take a look at where Moderna, Inc. (NASDAQ:MRNA) stands against the other stocks. US shares stayed firmer on Wednesday, with all major indices finally eking out ...